Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088109 | 0.92 | SIGMAR1 (0.42) | CXCR4MEN1CHRM2CHRM1KMT2A | |
| Hydrochloric Acid SCHEMBL572488 | 0.90 | SIGMAR1 (0.41) | CXCR4CHRM2CHRM1SIGMAR1CHRM5 | |
| Hydrochloric Acid SCHEMBL571818 | 0.90 | SIGMAR1 (0.41) | CXCR4CHRM2CHRM1SIGMAR1CHRM5 | |
| SCHEMBL12932939 | 0.83 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL2092827 | 0.80 | PSMB1 (0.35) | MEN1KMT2ATDP1HRH3ALDH1A1 | |
| SCHEMBL28338561 | 0.80 | — | — | |
| SCHEMBL24122600 | 0.80 | CXCR4 (0.57) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL9063069 | 0.79 | SIGMAR1 (0.36) | CHRM2CHRM1SIGMAR1CHRM5CHRM3 | |
| SCHEMBL18978019 | 0.78 | CXCR4 (0.46) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL9444446 | 0.78 | MEN1 (0.39) | MEN1KMT2ATDP1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3468953-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | CXCR4 913/4885MEN1 2146/4885CHRM2 163/4885 |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | DNMT1, DNMT3A, DNMT3B | CXCR4 684/4885MEN1 1594/4885CHRM2 1606/4885 |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | DNMT1, DNMT3A, DNMT3B | CXCR4 684/4885MEN1 1594/4885CHRM2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.